Back to search

Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis

NCT02869802

NULLOBSERVATIONAL
British Columbia Cancer Agency
190 participants
Started 2016-10-06 · Completed 2027-12
Status: Recruiting (as of 12-23-2025)

Conditions

CancerPancreatic Cancer

Linked Papers (from SciSciNet-V2)

Total Papers35
Background
19
Result
0
Derived
0
Unknown
16

Total Citations Per Year

Brief Summary

Researchers are looking for better ways of understanding and treating pancreatic cancer. The purpose of this study is to see how useful it is to look for changes and characteristics in your genes (molecules that contain instructions for the development and functioning of the cells) and the genes within the tumour. These characteristics may be useful in choosing treatments for patients in the future. Changes (mutations) in genes have been shown to be an important characteristic in cancers. Looking at differences in genes in patients with advanced pancreatic ductal adenocarcinomas and comparing this information with response to their initial chemotherapy treatment may help to learn which treatments may be better for certain patients after initial treatment.

Sort by:

Background Papers38

Signatures of mutational processes in human cancer
2013
8,907 citations
Signatures of mutational processes in human cancer
2013
8,907 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
2015
7,057 citations
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
2015
7,057 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
2013
5,748 citations
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
2013
5,748 citations
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
2014
4,342 citations
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
2014
4,342 citations
Whole genomes redefine the mutational landscape of pancreatic cancer
2015
2,373 citations
Whole genomes redefine the mutational landscape of pancreatic cancer
2015
2,373 citations
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
2013
2,359 citations
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing
2013
2,359 citations
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
2015
1,985 citations
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
2015
1,985 citations
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
2012
1,918 citations
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
2012
1,918 citations
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
2019
1,779 citations
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
2019
1,779 citations
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
2015
1,716 citations
Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma
2015
1,716 citations
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
2011
1,639 citations
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
2011
1,639 citations
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014
1,551 citations
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014
1,551 citations
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
2009
798 citations
Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene
2009
798 citations
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
2009
540 citations
MicroRNAs in Plasma of Pancreatic Ductal Adenocarcinoma Patients as Novel Blood-Based Biomarkers of Disease
2009
540 citations
ATM Mutations in Patients with Hereditary Pancreatic Cancer
2011
468 citations
ATM Mutations in Patients with Hereditary Pancreatic Cancer
2011
468 citations
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
2014
393 citations
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
2014
393 citations
New targeted therapies in pancreatic cancer
2015
46 citations
New targeted therapies in pancreatic cancer
2015
46 citations
Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis
2017
36 citations
Impact of Concurrent Medication Use on Pancreatic Cancer Survival—SEER-Medicare Analysis
2017
36 citations
Temporal Dynamics of Genomic Alterations in a BRCA1 Germline–Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan
2018
1 citations
Temporal Dynamics of Genomic Alterations in a BRCA1 Germline–Mutated Pancreatic Cancer With Low Genomic Instability Burden but Exceptional Response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan
2018
1 citations

Result Papers0

No result papers linked

Derived Papers0

No derived papers linked

Unknown Papers16

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008
25,031 citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
2015
8,174 citations
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011
6,637 citations
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
2014
3,906 citations
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007
3,700 citations
Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database11No competing interests declared.
1999
786 citations
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
1996
781 citations
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
1996
577 citations
BRCA2 Germline Mutations in Familial Pancreatic Carcinoma
2003
482 citations
Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma
2015
353 citations
Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature.
2008
242 citations
NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer
2018
205 citations
Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
2013
183 citations
Feasibility of Identifying Pancreatic Cancer Based on Serum Metabolomics
2011
151 citations
Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma
2015
56 citations
The Current State of Pancreatic Cancer in Canada
2014
22 citations